Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01530 3SBIO
RTNominal up5.980 +0.240 (+4.181%)
Others

21/01/2020 15:15

{I-bank focus}Citi lowers 3SBio (01530) to HK$16; "buy"

[ET Net News Agency, 21 January 2020] Citi Research lowered its target price for 3SBio
(01530) to HK$16 from HK$25 and maintained its "buy" rating.
The research house said 3SBio's major drug YiSaipu (YSP) is under pressure after its
competitor Humira and Remicade NRDL (National Reimbursement Drugs List) inclusion. Humira
accepted 60% ASP cut and annual cost comes to Rmb33.6K. While YSP does not cut ASP but
adopted new PAP (patient assistance program) strategy of "buy 20 and get 28 for free" with
annual cost down to Rmb19.3K at a 42% discount to Humira's NRDL price.
Citi lowered its FY2019-21 earnings by 3-12%. While most investors are concerned about
the company's growth in the next few years, Citi thinks further valuation re-rating
requires stronger execution capability and better sales delivery. (KL)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.